Carvedilol Diminishes Cardiac Remodeling Induced by High-Fructose/High-Fat Diet in Mice via Enhancing Cardiac β-Arrestin2 Signaling

J Cardiovasc Pharmacol Ther. 2020 Jul;25(4):354-363. doi: 10.1177/1074248420905683. Epub 2020 Feb 13.

Abstract

Background: Insulin resistance (IR) is a well-known risk factor for cardiovascular complications. This study aimed to investigate the effect of a dietary model of IR in mice on cardiac remodeling, cardiac β-arrestin2 signaling, and the protective effects of carvedilol as a β-arrestin-biased agonist.

Methods and results: Insulin resistance was induced by feeding mice high-fructose/high-fat diet (HFrHFD) for 16 weeks. Carvedilol was adiministered for 4 weeks starting at week 13. At the end of the experiment, body weight, heart weight, left and right ventricular thickness, visceral fat weight, fasting blood glucose (FBG), serum insulin, IR index, and serum endothelin-1 were measured. In addition, cardiac tissue samples were histopathologically examined. Also, cardiac levels of cardiotrophin-1, β-arrestin2, phosphatidylinositol 4,5 bisphosphate (PIP2), diacylglycerol (DAG), and phosphoserine 473 Akt (pS473 Akt) were measured. Results showed significant increases in the FBG, serum insulin, IR index, serum endothelin-1, cardiac DAG, cardiac fibrosis, and degenerated cardiac myofibrils in HFrHFD-fed mice associated with a significant reduction in cardiac levels of cardiotrophin-1, β-arrestin2, PIP2, and pS473 Akt. On the other hand, carvedilol significantly reduced the heart weight, FBG, serum insulin, IR index, serum endothelin-1, cardiac DAG, left ventricular thickness, right ventricular fibrosis, and degeneration of cardiac myofibrils. In addition, carvedilol significantly increased cardiac levels of cardiotrophin-1, β-arrestin2, PIP2, and pS473 Akt.

Conclusion: Carvedilol enhances cardiac β-arrestin2 signaling and reduces cardiac remodeling in HFrHFD-fed mice.

Keywords: cardiac remodeling; carvedilol; insulin resistance; β-arrestin.

MeSH terms

  • Animals
  • Cardiomegaly / etiology
  • Cardiomegaly / metabolism
  • Cardiomegaly / physiopathology
  • Cardiomegaly / prevention & control*
  • Carvedilol / pharmacology*
  • Cytokines / metabolism
  • Diet, High-Fat
  • Dietary Sugars
  • Disease Models, Animal
  • Fibrosis
  • Fructose
  • Insulin Resistance*
  • Male
  • Mice
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / metabolism
  • Myocytes, Cardiac / pathology
  • Phosphatidylinositol 4,5-Diphosphate / metabolism
  • Phosphorylation
  • Proto-Oncogene Proteins c-akt / metabolism
  • Signal Transduction
  • Ventricular Function, Left / drug effects*
  • Ventricular Function, Right / drug effects*
  • Ventricular Remodeling / drug effects
  • beta-Arrestin 2 / agonists*
  • beta-Arrestin 2 / metabolism

Substances

  • Arrb2 protein, mouse
  • Cytokines
  • Dietary Sugars
  • Phosphatidylinositol 4,5-Diphosphate
  • beta-Arrestin 2
  • Carvedilol
  • Fructose
  • cardiotrophin 1
  • Proto-Oncogene Proteins c-akt